Ohio State Navbar


Jon Von Visger, MD

Staff photo

395 W 12th Ave
Columbus, OH 43210

Phone: (614) 293-4997

Email: von-visger.1@osu.edu


Current OSU Appointments

Assistant Professor-Clinical, Nephrology

Physician, FGP-Nephrology



My areas of focus are in nephrology and transplant medicine in the clinical excellence track with particular goals to improve renal recovery and transplant outcomes. My main efforts have been in two high-impact areas of renal transplant recipient care, acute kidney injury/delayed graft function and antibody mediated diseases/rejection. All of these efforts have the specific goals directed to prevent renal failure and prolong renal transplant function and survival.

Education/mentoring: At the national/international level I coauthored transplant educational modules for transplant infectious disease trainees, and served on the American Society for Transplantation (AST) transplant educational committees (providing services and programs for trainees and support staff). I have also presented the American College of Physicians board review preparation and currently serve as reviewer for Nephsap/KSAP review modules for Nephrology and Transplant certification. Transplant is almost a niche specialty when compared to general nephrology or general medicine. While the opportunities for training for specialists in this field is limited to major academic centers, material from this represents nearly 20% of material for nephrology medicine board questions. Being selected as reviewer for the transplant section of NephSAP (nephrology self-assessment program) by the American Society for Nephrology is major recognition.
At OSU, I provided a transplant immunology lecture for the IBGP course for several years (see courses taught) with good student responses and evaluations. This is a good way to catch enthusiasm of potential future researchers/practitioners in immunology and transplant.

Scholarship: I have been site-principal investigator in several national and international clinical and device trials with significant impacts on management of kidney injury and transplant patients. Most have resulted in international publications for multicenter trials including; renal assist device for acute kidney injury recovery, a novel cross-match test for transplant risk of rejection, and calcium and mineral management post transplant (see publications). I currently am principal investigator in two more industry-sponsored studies in renal disease described below and expect international impact publications from both

I have presented several abstracts related to delayed graft function (DGF) and medication interactions as well as its effects on graft and patient mortality at national meetings (see scholarly presentations and abstracts) and am awaiting acceptance for publication of a journal manuscript for the same.
I have authored and attained an IND application from the FDA for the use of a novel drug, Belatacept, in the management of DGF, and am currently enrolling in an Industry funded Investigator initiated trial from Bristol-Myers Squibb: one of only three funded last year for Belatacept. To date, there is little knowledge/evidence for therapy at improving DGF outcomes, and the Belatacept trial has the potential for a landmark study. Preliminary results were presented by me this year at our annual AST meeting. Industry support for this study includes more than $ 4000 per month treatment/medication costs per patient as well as coordinator/administration and regulatory fees.

In the area of antibody related transplant diseases, I am primary author on research related to recurrence of IgA nephropathy at our center, and have chaired sessions and served as abstract reviewer at the AST and World Transplant Congresses for antibody-mediated rejection. I am co-author of our OSU antibody mediate rejection treatment protocol with Ron Pelletier in transplant surgery.
Together, DGF and antibody mediate rejection contribute to a more than 30% reduced 3 year transplant graft survival

I am currently site principal investigator enrolling patients in a second industry sponsored international trial for novel treatment of autosomal dominant polycystic kidney disease (the most common single gene related cause for renal failure: 1 in 400-1000) and resulting in need for transplant. We are one of 15 centers in the US and have currently completed the randomized prospective placebo controlled study (continued data collection), and have initiated a follow-up dose-response study. This therapy has been approved in Europe and Canada and our U.S. primary study results are expected to be published later this year. Industry support for these studies include more than $ 5000 per month/patient support in medication, clinical visits and additional regulatory/administration fees. 2016 funds totaled 54,400 for this study.

Both studies are listed on the clinicaltrials.gov website with national and international exposure, and result in increased referrals to OSU from local and regional referring nephrologists.

In another, OSU-only clinical trial, I am working with collaborators across several disciplines to evaluate a novel biological detection process using immunologically modified field-effect transistors. This device was invented by OSU faculty and has attained NIH small industry funding.These have the potential to detect picomolar levels of inflammatory citokines that might be used to diagnose rejection in biologic fluids and we are currently assessing the utility in detection of rejection in renal transplant patients, resulting in several abstract presentations.

While I actively recruit clinical trials to OSU, I am also often sought out as PI by sponsors due to my successful enrollment and contributions to previous studies. Many patients come to OSU specifically to participate in these clinical trials not available elsewhere

Service: My primary area of expertise is in Transplant Nephrology and highest impact activities are directed through renal transplant and what I am best recognized for. However, my service extends to the broader community in several areas. I currently am a member of four different national committees for the American Society of Transplantation including Transplant Diagnostics, Donor Advocacy, Transplant Infectious Disease, and Allied Health Professionals Communities of Practice and have been recognized for my contributions by selection for leading antibody research sections, and contributing to education programs. I have also given several regional presentations/CME talks sponsored by NKF and OSU for outreach. Additionally, I participated in regional NKF sponsored free kidney disease screenings (KEEP Program from 2006 to 2014). Anonymously I was nominated and listed in Consumers Research Council’s America’ Top Physicians for 2012.

At OSU I have served on several University, hospital and departmental committees including faculty council and college assembly over the last 5 years: representing the department of medicine for discussion of University policies and other active issues solicited from colleagues. I have serve on the hospital formulary committee for the last 10 years, reviewing new medications petitions for approval and have occasionally served as chair of this committee. Within the department of medicine, I represent our renal division on the clinical operations, quality and safety committee discussing current policies, quality metrics and initiatives for improvement in patient care and satisfaction.
As part of a best practices review, I co-authored recommendations for diagnosis and treatment of hyponatremia (with Harrison Weed). As renal division quality director, I conduct our quarterly division reviews as well as complete clinical practice reviews for new faculty.

Within our OSU Comprehensive Transplant Center, I serve on several committees for quality as well as chair our pre-transplant selection committee, which meets weekly to review potential kidney recipient donor/recipient candidates. I also represent our nephrology group on our CTC Clinical Quality Committee, Chaired by Susan Moffatt-Bruce, reviewing goals for quality improvement as well as expanding patient transplant.

Within the first 4 months of this calendar year, OSU has moved from 40th in 2015 to 4th in the nation in total transplants. I am one of four transplant nephrologists at OSU and provide 6.5+ months of in-patient service to cover in-patient and consultation support. In addition, I maintain 2 half-day clinics per week year-round. As I focus on recurrent diseases and antibody mediated rejection, a significant portion of my clinic time is devoted to these patients, and this number has risen from approximately 15 to 53 during the last 3 years as more referrals are directed to me for this. These patients require more frequent and specialized care including specialty medications and infusions and testing. While these patients tend to be more demanding and relatively unhappy about these events, I have generally maintained a high level of patient satisfaction and low mortality indexes (shown in attached documents) and received an award/certificate of excellence in 2010 for outstanding patient service with a satisfaction rate above 95%. My clinical RVUs have also exceeded my division goals by more than 20% for the last 2 years with the growth in in-patient and transplant referrals.

Academic Advising

2012 - present anthony alvarado, The Ohio State University. Graduated 2013.
2016 - present Andrew Detty, The Ohio State University.
2007 - 2008 Fawn Langerman, The Ohio State University. Graduated 2008.


Von Visger, Jon. Studies Relating to Neural Regeneration: 1. A Neurite-Promoting Factor Derived From Striated Muscle, and 2. Differentiation of Progenitor Cells for Newborn Rat Forebrain.. Baltimore, MD, US|USA: University Microfilms Inc, January 1996.



1999 - present MD: Commonwealth of Massachusetts Board of Registration in Medicine
1999 - present MD: American Board of Internal Medicine
2004 - present Board Certified Nephrology: American Board of Internal Medicine
2005 - present MD: State Medical Board of Ohio

Clinical Services

07/01/2005 Assistant Professor (clinical) (start date July 2005) (The Ohio State University)


1986 B.S., UCLA Los Angeles California

1988 M.S., UCLA Los Angeles California

1996 M.D./Ph.D., University of Maryland

2003 None Indicated, Combined Massachusetts General Hospital


Editorial Activities

2006 - present arthritis and rheumatism
2008 - present clinical nephrology
2010 - present Transplantation
2012 - present Ibnosina


2010 - present Certificate of Excellence in Patient Service. The Ohio State Unviversity Wexner Medical Center.
2012 - present America's Top Physicians. Consumer Research Council.

Journal Articles

Arakawa, T., J. Von Visger, M. McGinley, M.F. Rohde, G.M.Fox, and L.O. Narhi. "Alteration in Folding Efficiency andConformation of Recombinant Human Tumor Necrosis Factor-alpha by Replacing Cysteines 69 and 101 with Aspartic Acid 69 and Arginine 101." Protein Engineering. Vol. 8, no. 3. (January 1990.): 721-724.

Von Visger, J, R; Yeon, D, S; Oh, T, H; Markelonis, G J. "Differentiation and maturation of astrocytes derived from neuroepithelial progenitor cells in culture.." Experimental neurology. Vol. 128, no. 1. (January 1994.): 34-40.


Oh, T, H; Markelonis, G, J; Von Visger, J, R; Baik, B; Shipley, M T. "Acidic pH rapidly increases immunoreactivity of glial fibrillary acidic protein in cultured astrocytes.." Glia. Vol. 13, no. 4. (January 1995.): 319-22.

Francis, J, W; Von Visger, J; Markelonis, G, J; Oh, T H. "Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum.." Neurotoxicology and teratology. Vol. 17, no. 1. (January 1995.): 7-12.



Von Visger, Jon; Magee, Colm. "Low molecular weight heparins in renal failure.." Journal of nephrology. Vol. 16, no. 6. (January 2003.): 914-6.

Von Visger,J; Magee,C. "Low molecular weight heparins in renal failure." JOURNAL OF NEPHROLOGY. Vol. 16, no. 6. (November 2003.): 914-916.

Von Visger,J; Magee,C. "Low molecular weight heparins in renal failure." JOURNAL OF NEPHROLOGY. Vol. 16, no. 6. (November 2003.): 914-916.

Pesavento,Todd,E; Nori,Uday; Von Visger,Jon; Henry,Mitchell,L; Ferguson,Ronald,M. "Sirolimus, independent of cyclosporine, is associated with worsened proteinuria in renal transplantation.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 7, (May 2007.): 264-264.

Jackson,Annette,M; Zachary,Andrea,A; Breimer,Michael,E; Rydberg,Lennart; Klimmalm,Goran,B; Smith,Douglas,M; Pelletier,Ron,M; Von Visger,Jon; Williams,Winfred,W; Saidman,Susan,L; Holgersson,Jan; Tyden,Gunnar; Holgersson,Suchitra; Grufman,Per. "Clinical trial data evaluating the XM-One endothelial cell crossmatch test in predicting early rejection episodes in renal transplantation.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 7, (May 2007.): 201-202.

Von Visger,Jon; Pesavento,Todd; Nori,Uday; Elkhammas,Elmahdi. "Prolonged early graft dysfunction with sirolimus and association with mortality in renal transplant recipients.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 7, (May 2007.): 533-534.

Von Visger,Jon; Pesavento,Todd; Nori,Uday. "Increased mortality risk for renal transplant recipients on sirolimus and delayed graft function: A review of 74,000 patients.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 7, (May 2007.): 163-163.

Von Visger,Jon; Adams,Pat; Dipaola,Nicholas. "A new endothelial progenitor cell flow-based method for donor-recipient cross-making detects donor-specific endothelial antigens.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 7, (May 2007.): 499-500.

Moffat-Bruce, S., T. Pesavento J. Von Visger, D. Nunley, A. Pope-Harman, S. Martin, P. Ross. "Successful Management of ImmunoSuppression in a Patient with Sever Hyperammonemia After Lung Transplantation." J. Heart and Lung Transplant. Vol. 27, no. 7. (July 2008.): 801-803.

Breimer ME, L Rydberg, A Jackson, D Lucas, A Zachary, J Melancon, J Von Visger, R Pelletier, S Saidman, W Williams,Jr., J Holgersson, G Tyden, G Klintmalm, S Coultrup, S Sumitran-Holgersson, and P Grufman. "Multicenter Evaluation of a Novel Endothelial Cell Crossmatch Test in Kidney Transplantation." Transplantation. Vol. 27, no. 87 (4). (January 2008.): 549-556.

Breimer M.E., L. Rydberg, A. Jackson, D. Lucas, A. Zachary, J. Melancon, J. Von Visger, R. Pelletier, S. Saidman, W.W. Williams, J. Holgersson, G. Tyden, G Klintmalm, S. Coultrup, S. Sumatran-Holgersson, and P. Grufman. "Multicenter Evaluation of a Novel Endothelial Cell Crossmatch Test in Kidney Transplantation." Transplantation. (January 2008.): -.

Nori,Uday,S; Pesavento,Todd,E; Davies,Elizabeth,A; Von Visger,Jon; Miller,Becky,S; Ferguson,Ronald,M. "Randomized, prospective prednisone (P) withdrawal trial in kidney transplant patients treated with Sirolimus (S) vs. microemulsified cyclosporine (CsA) based regimens.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 8, (May 2008.): 301-301.

Moffat-Bruce, S, Pesavento, T, Von Viger, J, et al.. "Successful Management of Immunosuppression in a Patient With Severe Hyperammonemia After Lung Transplant." The Journal of Heart and Lung Transplantation. Vol. 27, no. Issue 7. (July 2008.): 801-803.

Pesavento,Todd,E; Winoto,Johan; Nori,Uday,S; Von Visger,Jon,R; Singh,Neeraj. "Risk of Recurrent Focal Segmental Glomerulosclerosis (FSGS) in Patients Following Loss of Native Kidneys and Primary Transplant from Recurrent FSGS. Is Retransplantation Prudent?." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 9, (January 2009.): 685-685.

Pesavento,Todd,E; Nori,Uday,S; Satoskar,Anjali; Dils,Dorrie; Henry,Mitchell,L; Von Visger,Jon,R; Singh,Neeraj. "Use of Baseline Kidney Biopsies (BX) and Pulsatile Perfusion Parameters To Predict Graft Outcome in Deceased Donor (DD) Kidney Transplants.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 9, (January 2009.): 313-313.

Humes HD, Sobota JT, Ding F, Song JH and the RAD Study Group. "A Selective Cytopheretic Inhibitory Device to Treat the Immunological Dysregulation of Acute and Chronic Renal Failure." Blood Purif. Vol. 1, no. 29 (2). (January 2010.): 183-190.

Brodsky,Sergey; Hebert,Lee; Wu,Haifeng; Liu,James; Ware,Kyle; Brodsky,Polina; Chen,Robert; Von Visger,Jon. "Increased INR > 3.0 In Patients on Warfarin Therapy Is Associated with Acute Changes In the Serum Creatinine and Increased Mortality Rate." BLOOD. Vol. 116, no. 21. (November 2010.): 358-358.

Singh,Neeraj; Gunay,Yusuf; Samavedi,Srinivas; Samir,Parikh; Von Visger,Jon; Nori,Uday; Pesavento,Todd; Henry,Mitchell; Elmahdi,Elkhammas. "Recurrence of IgA Nephropathy Post Kidney Transplantation in Steroid Free vs. Steroid Dependent Immunosuppression Protocol.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 10, (April 2010.): 519-520.

Parikh,Samir; Yusuf,Gunay; Srinivas,Samavedi; Ravish,Shah; Jon,Von,Visger; Uday,Nori; Amer,Rajab; Todd,Pesavento; Neeraj,Singh. "Cardiac Stress Test as a Risk Stratification Tool for Early Post Kidney Transplant (KTx) Cardiovascular (CV) Outcomes in Diabetic ESRD Patients.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 10, (April 2010.): 306-306.

Nori,Uday,S; Agarwal,Anil,K; Von Visger,Jon,R. "Dietary Therapy in Hypertension." NEW ENGLAND JOURNAL OF MEDICINE. Vol. 363, no. 16. (October 2010.): 1580-1581.

Ware,Kyle; Brodsky,Polina; Satoskar,Anjali,A; Nadasdy,Tibor; Nadasdy,Gyongyi; Wu,Haifeng; Rovin,Brad,H; Bhatt,Udayan; Von Visger,Jon; Hebert,Lee,A; Brodsky,Sergey,V. "Warfarin-Related Nephropathy Modeled by Nephron Reduction and Excessive Anticoagulation." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. Vol. 22, no. 10. (October 2011.): 1856-1862.

Albawardi,Alia; Satoskar,Anjali; Von Visger,Jon; Brodsky,Sergey; Nadasdy,Gyongyi; Nadasdy,Tibor. "Proliferative Glomerulonephritis With Monoclonal IgG Deposits Recurs or May Develop De Novo in Kidney Allografts." AMERICAN JOURNAL OF KIDNEY DISEASES. Vol. 58, no. 2. (August 2011.): 276-281.

Singh,Neeraj; Parikh,Samir; Bhatt,Udayan; VonVisger,Jon; Nori,Uday; Hasan,Ayesha; Samavedi,Srinivas; Andreoni,Kenneth; Henry,Mitchell; Pelletier,Ronald; Rajab,Amer; Elkhammas,Elmahdi; Pesavento,Todd. "Cardiac Stress Test as a Risk-Stratification Tool for Posttransplant Cardiac Outcomes in Diabetic Kidney Transplant Recipients." TRANSPLANTATION. Vol. 94, no. 12. (December 2012.): 1224-1229.

Nori,U,S; Shah,R; HADDAD,N,J; Von Visger,J; Agarwal,A,K. "Management of Renal Transplant Recipients with Failing Allografts and Transitioning to Renal Replacement Therapy." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 12, (May 2012.): 493-493.

Von Visger,J; Singh,N; MacAleese,R; Pelleteir,R; Nori,U; PESAVENTO,T; Andreoni,K; Winters,H; Nadasdy,T; Brodsky,S; Satoskar,A; Forbes,R. "Response to Therapy and Predictors of Graft Survival in Antibody Mediated Rejection." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 12, (May 2012.): 418-419.


Parikh,Samir; Nagaraja,Haikady; Agarwal,Anil; Samavedi,Srinivas; Von Visger,Jon; Nori,Uday; Andreoni,Kenneth; Pesavento,Todd; Singh,Neeraj. "Impact of post-kidney transplant parathyroidectomy on allograft function." CLINICAL TRANSPLANTATION. Vol. 27, no. 3. (May 2013.): 397-402.

Roth,Rachel; Parikh,Samir; Makey,Dayanand; Foster,Jamison; Rozenblit,Grigory; Satoskar,Anjali; Nadasdy,Gyongyi; Von Visger,Jon; Hebert,Lee; Rovin,Brad,H; Nadasdy,Tibor; Brodsky,Sergey,V. "When Size Matters: Diagnostic Value of Kidney Biopsy according to the Gauge of the Biopsy Needle." AMERICAN JOURNAL OF NEPHROLOGY. Vol. 37, no. 3. (January 2013.): 249-254.

Pelletier,R; Von Visger,J; Adams,P; Henry,M. "The Outcome of Luminex Single Antigen Bead DSA Detection in Post-Transplant Alloantibody Producing Recipients Does Not Correlate with Differential Graft Loss.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 13, (April 2013.): 418-419.

Von Visger,J; PESAVENTO,T; Pelletier,R; Diez,A; Nori,U. "Tolerance of ACE-Inhibitor/ARB Use Post Renal Transplant.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 13, (April 2013.): 355-356.

Theiss,A; Wang,Y; CASAL,P; Lee,S; Hadley,G; Von Visger,J; Lu,W; BRILLSON,L; Singh,N. "Immunologically Modified FETs for Protein Detection in Biologic Fluids.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 13, (April 2013.): 228-228.

Hulbert,A; Rajab,A; Von Visger,J; Winters,H. "Examination of Infectious Complications with Plasmapheresis in Combination with Anti-Thymocycte Globulin for the Treatment of Acute Rejection.." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 13, (April 2013.): 330-330.

Qamri,Zahida; Pelletier,Ronald; Foster,Jamison; Kumar,Sunil; Momani,Hammam; Ware,Kyle; Von Visger,Jon; Satoskar,Anjali; Nadasdy,Tibor; Brodsky,Sergey,V. "Early posttransplant changes in circulating endothelial microparticles in patients with kidney transplantation." TRANSPLANT IMMUNOLOGY. Vol. 31, no. 2. (August 2014.): 60-64.

Von Visger,J,R; Gunay,Y; Andreoni,K,A; Bhatt,U,Y; Nori,U,S; Pesavento,T,E; Elkhammas,E,A; WINTERS,H,A; Nadasdy,T; Singh,N. "The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression." CLINICAL TRANSPLANTATION. Vol. 28, no. 8. (August 2014.): 845-854.

Kalantar-Zadeh,K; Von Visger,J; Foster,C,E. "Overcoming the Body Mass Index as a Barrier in Kidney Transplantation." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 15, no. 9. (September 2015.): 2285-2287.

Singh,Neeraj; Von Visger,Jon; Zachariah,Mareena. "Extended release once a day tacrolimus." CURRENT OPINION IN ORGAN TRANSPLANTATION. Vol. 20, no. 6. (December 2015.): 657-662.

Wolf,Myles; Weir,Matthew,R; Kopyt,Nelson; Mannon,Roslyn,B; Von Visger,Jon; Deng,Hongjie; Yue,Susan; Vincenti,Flavio. "A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation." TRANSPLANTATION. Vol. 100, no. 1. (January 2016.): 184-193.

Von Visger, J, Gunay, Y, Andreoni, K, et al. "Risk for Recurrence of IGA Nephropathy After Transplant in Steroid Free Regimen, and Other Immunosuppression." Clinical Transplantation. -.


Reference Works

January 1986 Ruettinger, R T., J. Von Visger, A.J. Fulco."Relative Induction of Three Distinct Cytochrome P-450 Species in Twelve Strains of Bacillus Megaterium" philadelphia.
January 1993 Von Visger, J., T.H. Oh, D.S. Yeon, G.J. Markelonis."Maturation of CNS Stem Cells from New Born Rat Forebrain in a Defined Medium" New york.
January 1995 Oh, T H; G. Markelonis, J. Von Visger, B. Baik, M.T. Shipley, M T."Acidic pH Increases Immunoreactivity of GFAP in Cultured Rat Astrocytes" philadelphia.
June 2005 Linde, P., J. Von Visger, K. Maxwell, J. Brotherton, C. Conlin, A.B. Cosimi, W.W. Williams."Enhancing In Vitro Clearance of Small Molecule Toxins Using a Novel CVVH-Based Recirculation Loop: Implicationsfor Bioartificial Liver Support Systems and Renal Replacement Therapies" philadelphia.
January 2006 Pesavento, T., E. Davies, J. Von Visger, U. Nori, B. Miller, R.M. Ferguson."Randomized, Prospective Prednisone Withdrawl Trial in Kidney Transplant Patients Treated with Mycophenolate Sodium Comparing Rapamycin vs C2 Dosed Cyclosporine" philadelphia.
October 2007 Dipaola, N., J. Von Visger, P. Adams."Acute Humoral Rejection Mediated By Donor Specific Anti-Endothelial Antibodies Detected Using XM-One" New York.
May 2007 Pesavento T., U. Nori, J. Von Visger, M. Henry, R. Ferguson."Sirolimus, Independent Of Cyclosporine, Is Associated With Worsened Proteinuria In Renal Transplantation" malden.
May 2008 Nori, U.S., T. Pesavento, E. Davies, J. Von Visger, B. Miller, R. M. Ferguson."Randomized Prospective Prednisone Withdrawl Trial In kidney Transplant Patients Treated with Sirolimus vs. Microemulsified Cyclosporine Based Regimens" Malden.
August 2008 Zachary, A. A Jackson, J. Melancon, M. Breimer, L. Ryderberg, J. Von Visger, R. Pelletier, S. Saidman, W.W. Williams, G. Klintmalm, S. Coultrup, J. Holgersson, G. Tyden, S. Holgersson, P. Grufman."Final Clinical Trial Data Evaluating The XM-One Endothelial Crossmatch Test In Predicting Early Rejection Episodes in Renal Allograft Recipients." Malden.
January 2009 Humes H D, Dillon J, Tolwani AJ, Cremisi H, Wali R, Murray P, Ye J, Chawla LS, Vijayan A, Finkel, KW Kraus,M, Atta M, Von Visger J, Block GA, Charytan D, and Vinnikova AK."A Novel Selective Cytopheretic Inhibitory Device (SCD) Improves Mortality in ICU Patients With Acute Kidney Injury (AKI) and Multiorgan Failure (MOF) In a Phase II Clinical Study" Unionville, CT.
April 2010 Parikh, S, Gunay, Y, Srinivas, S, Shah, R, Von Visger, J, Nori, U, Rajab, A, Pesavento, T, Sing."Cardiac Stress Test as a Risk Stratification Tool for Early Post Kidney Transplant Cardiovascular Outcomes in Diabetic ESRD Patients" Malden. : 306
April 2012 Alvarado, A, Casal, P, Theiss, A, Wang, Y, Hadley, G, Singh, N, Brillson, L, Pelletier, R, Lu, W, Lee, S, and Von Visger, J."Monitoring of Transplant Graft Status by Immunologically Modified Field Effect Transistors" columbus.
May 2012 Wier, M, Vincenti, F, Von Visger, J, Kopyt, N, Mannon, R, Tseng, S, Goodman, W, and Wolf, M.."Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients: A Propspective Cohort Study" Malden.
May 2012 Vincenti, F, Weir, Von Visger, J, et al."A Prospective Cohort Study of Persistent Hyperparathyroidism in Kidney Transplant Recipients" Unionville. : 8
May 2012 Nori, U, Shah, R, Haddad, N, Von Visger, J, Agarwal, A."Management of Renal Transplant Recipients with Failing Alolgrafts and Transitioning to Renal Replacement Therapy" Malden. : 493
May 2012 Andreoni, K, Elkhammas, E, Rajab, A, Pelletier, R, Bumgardner, G, Forbes, R, Singh, N, Von Visger, J, Pesavento, T, Davies, E, Nori, U, Henry, M."Influence of BMI and Age on Simultaneous Kidney-Pancreas Recipients" malden.
April 2013 Pelletier, R, Von Visger, J, Adams, P, and Henry, M."The Outcome of Luminex Single Antigen Bead DSA Detection in Post-Transplant Alloantibody Producing Recipients Does Not Correlate with Differential Graft Loss" Malden. : 418
May 2015 Diez A, Von Visger J, Nori U, Pesavento T, Henry M, Davies E and Pelletier R.""What's the Mileage" Determining the Length of Time in Which Renal Function Returns to Pre-Calcineurin Discontinuation Levels in Patients with Interstitial Fibrosis" malden.
June 2015 Leino A, Hulber A, Delahunty A, Rajab A, Von visger, J, Winters H."Infectious Complications with Plasmapheresis in Combination with Antithymocyte Globulin Compared to Antithymocyte Globuline Alone in the Treatment of Acute Rejection" malden.
June 2016 Diez A, Kang R, Von Visger J, Nori U, Pesavento T, Rajab A, Henry M, and Pelletier R."Renal Efficiency: A New Metric for Evaluating Kidneys in Living Donors" malden.
May 2017 Diez A, Diltz G, Von Visger J, Nori U, Pesavento T, Pelletier R."Predicting Residual Renal Compensation in Living Kidney Donors Post-Donation" malden.
May 2017 Pesavento T, Diez A, Pelletier R, Nori U, Von Visger J."Renal Function Outcomes of Hypertensive Living Kidney Donors (HLD) and Recipients of HLD Kidneys: Results of a Case Control Study" malden.
May 2017 Von Visger J, Diez A, Nori U, Pesavento T, Pelletier R, Rajab A, El Hinnawi A, and Winters H."Costimulatory Blockade in Delayed Graft Function" malden.

Inventions and Patents

Jon Von Visger. Investigator-Initiated Study, Study Design and Investigational New Drug use application. "IND for Prospective Randomized Trial of (Costimulatory Blockade) Belatacept Switch in Renal Transplant Patients with Delayed Graft Function." Bristol-Myers Squibb. filed 2014, (patent pending), and Application No. IM 103-336

Jon Von Visger, Amin Arnaout, Peter Linde, Alejandro Morales. devise system of isolation and characterize integrated cells after engraftment. "Kidney Precursor Stem Cells Flk1+, Sca-1+." Harvard. filed 2006, and Patent No. 2232



"A New Endothelial Progenitor Cell Flow-Based Method for Donr Recipient Cross-Matching Detects Donor-Specific Endothelial Antigens." Presented at American Transplant Congress, San Francisco, CA, US|USA. (May 2007)

"Prolonged Early Graft Dysfunction with Sirolimus and Association with Mortality in Renal Transplant Recipients." Presented at American Transplant Congress, San Francisco, CA, US|USA. (May 2007)

"Review of 90,866 Renal Transplants: Survival Imact of Sirolimus." Presented at American Transplant Congress, Toronto, CA|CAN. (May 2008)


"Response to Therapy and Predictors of Graft Survival in Antibody Mediated Rejection." Presented at American Transplant Congress, Boston, MA, US|USA. (June 2012)

"Tolerance of Ace-Inhibitor/ARB Use Post Renal Transplant." Presented at American Transplant Congress, Seattle, WA, US|USA. (May 2013)

"Immunologically Modified FETs for Protein Detection in Biologic Fluids." Presented at American Transplant Congress, seattle, WA, US|USA. (May 2013)

"Examination of Infectious Complications with Plasmapheresis in Combination with Anti-Thymocyte Globulin for the Treatment of Acute Rejection." Presented at American Transplant Congress, Seattle, WY, US|USA. (May 2013)

"Impact of Early Graft Dysfunction." Presented at World Transplant Congress 2014, San Francisco, CA, US|USA. (May 2014)

"Costimulatory Blockade in Delayed Graft Function." Presented at American Transplant Congress, Chicago, IL, US|USA. (May 2017)


Professional Activities

present consultant. AmGen. Thousand Oaks, CA.
present video interview. American Society for Transplantation.
2006 - present volunteer kidney screening. National Kidney Foundation. Columbus, OH.
2011 - present Judge volunteer. The Ohio State University. Columbus, OH.
2009 Television interview, promotion of National Kidney screening. National Kidney Foundation. Columbus, OH.
2010 Television interview, promotion of National Kidney screening. National Kidney Foundation. Columbus, OH.
2013 volunteer. Denman Forum. Columbus, OH.
2013 volunteer. Upper Arlington School systems. upper arlington, OH.

Unpublished Works

Leino A, Hulber A, Lehman A, Rajab A, Von visger, J, Winters H. Infectious Complications with Plasmapheresis in Combination with Antithymocyte Globulin for the Treatment of Acute Rejection in Renal Transplantation. June 2015.